Trial Profile

Open Label Extension Study for Patients with Parkinson's Disease with Dementia Previously Enrolled in ANAVEX2-73-PDD-001 Study for Continued Safety Assessment

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Blarcamesine (Primary)
Indications Dementia; Parkinson's disease
Focus Adverse reactions
Sponsors Anavex Life Sciences

Most Recent Events

30 Mar 2023 According to an Anavex Life Sciences Media Release, this study achieved both primary and secondary objectives.
30 Mar 2023 Results presented in an Anavex Life Sciences Media Release.
09 Aug 2022 According to Anavex Life Sciences media release, last patient last visit in study occurred this quarter and data expected by end of 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com